糖尿病肾病调脂治疗的临床应用被引量：4

Lipidlowering agents in diabetic nephropathy

在线阅读下载PDF

导出

摘要糖尿病肾病(DN)患者心血管事件的风险显著升高,与脂代谢紊乱密切相关。导致脂代谢紊乱的原因复杂多样,长期高血糖诱导血管内皮损伤能进一步增加胆固醇水平、降低高密度胆固醇水平。因此,调脂药物被临床广泛应用于DN的治疗。本文就调脂药物在DN中的临床应用及研究进展做一综述。 It is well known that patients with diabetic nephropathy have a high incidence of cardiovascular disease （CVD） .The mechanisms for dyslipidemia in diabetic nephropathy are muhifactorial and complex.Long-term hyperglycemia causes generalized vascular endothelial damage, leading to increased triglyceride levels and decreased high-density lipoprotein cholesterol. The implications of lipid lowering drugs in the treatment of diabetic nephropathy have been considered.The review focuses on the clinical efficacy and safety of lipid lowering drugs in the treatment of diabetic nephropathy.

作者潘瑜章海涛

机构地区南京军区南京总医院肾脏科国家肾脏疾病临床医学研究中心全军肾脏病研究所

出处《肾脏病与透析肾移植杂志》 CSCD 北大核心 2015年第2期176-180,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation

基金国家科技支撑计划课题(2013BAI09B04)(2015BAI12B05) 江苏省临床医学中心项目(BL2012007)

关键词糖尿病肾病血脂异常心血管事件调脂药物 diabetic nephropathy dyslipidemia cardiovascular disease lipid lowering drugs

分类号 R587.2 [医药卫生—内分泌]

引文网络
相关文献

参考文献34

1Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol,2014,18(2) :206-209.
2Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high- density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation,2001,104(25) :3046-3051.
3Bays HE, Jones PH, Brown WV, et al. National lipid association annual summary of clinical lipidology 2015.J Clin Lipidol, 2014,8 ( 6 Suppl) : S1-S36.
4Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta- analysis of 11 randomized controlled trials involving 21, 295 participants.Pharmacol Res ,2013,72:35-44.
5Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment:the FIELD Study.Diabetes Care,2012,35(2) :218-225.
6Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study.Diabetes Care, 2003,26( 5 ) : 1402-1407.
7Sacks FM,Hermans MP,Fioretto P, et al.Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus : a global case-control study in 13 countries.Circulation, 2014, 129(9) :999-1008.
8Turner RC, Millns H, Nell HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study ( UKPDS : 23 ). BMJ, 1998,316 ( 7134 ) : 823-828.
9Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilizationf rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation ,2014,129(8) :896-906.
10Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease.J Clin Invest,2014,124(6) :2333-2340.